1). Field of the Invention
This invention relates to a method and device for improving cardiac function.
2). Discussion of Related Art
Congestive heart failure annually leads to millions of hospital visits internationally. Congestive heart failure is a description given to a myriad of symptoms that can be the result of the heart's inability to meet the body's demand for blood flow. In certain pathological conditions, the ventricles of the heart become ineffective in pumping the blood, causing a back-up of pressure in the vascular system behind the ventricle.
The reduced effectiveness of the heart is usually due to an enlargement of the heart. A myocardial ischaemia may, for example, cause a portion of a myocardium of the heart to lose its ability to contract. Prolonged ischemia can lead to infarction of a portion of the myocardium (heart muscle) wherein the heart muscle dies and becomes scar tissue. Once this tissue dies it no longer functions as a muscle and cannot contribute to the pumping action of the heart. When the heart tissue is no longer pumping effectively, that portion of the myocardium is said to be hypokinetic, meaning that it is less contractile than the uncompromised myocardial tissue. As this situation worsens, the local area of compromised myocardium may in fact bulge out as the heart contracts, further decreasing the heart's ability to move blood forward. When local wall motion moves in this way it is said to be dyskinetic. The dyskinetic portion of the myocardium may stretch and eventually form an aneurysmic bulge. Certain diseases may cause a global dilated myopathy, i.e., a general enlargement of the heart when this situation continues for an extended period of time. As the heart begins to fail, the filling pressures increase, which stretches the ventricular chamber prior to contraction, greatly increasing the pressure (preload) to the heart. In response, the heart tissue remodels to accommodate the chronically increased filling pressures, further increasing the work that the now-compromised myocardium must perform. This vicious cycle of cardiac failure results in the symptoms of congestive heart failure such as shortness of breath on exertion, edema in the periphery, nocturnal dypsnia (a characteristic shortness of breath that occurs at night after going to bed), weight gain, and fatigue, to name a few. The enlargements increase stress on the myocardium. The stress increase requires a larger amount of oxygen supply, which can result in exhaustion of the myocardium leading to a reduced cardiac output of the heart.
According to one aspect of the invention, a method for improving cardiac function is provided. A membrane is inserted into a ventricle of the heart. The membrane is mounted in a position in the ventricle to substantially form a division between volumes of the ventricle on opposing sides of the membrane.
The invention is further described by way of examples with reference to the accompanying drawings, wherein:
As shown in
The anchoring formations 14 include a distal anchoring screw 14A, distal anchoring hooks 14B, and proximal anchoring hooks 14C. Two or more (in the present example, four) of the segments 22A are longer, and extend further down than other ones of the segments 22B. The segments 22A have their lower ends connected to one another, and the distal anchoring screw 14A is secured to the lower ends of the segments 22A. The segments 22A and 22B may be curved, as opposed to being straight, as shown in the figures.
The distal anchoring hooks 14B are secured to lower ends of the segments 22B. Each distal anchoring hook 14B curves out and then down and is formed with a lower sharp end 26.
The proximal anchoring hooks 14C are secured to upper ends of the segments 22A and 22B. Each one of the proximal anchoring hooks 14C curves out and then up and terminates in an upper sharp end 28. The anchoring hooks 14B and 14C move together with the main frame 18 toward the vertical axis 24 when the main frame 18 is collapsed.
As shown in
Referring to
As shown in
Reference is now made to
The catheter 44 is steered so that the distal anchoring screw 14A contacts a base of the bulge 76. The catheter 44 is then rotated so that the distal anchoring screw 14A screws into the myocardium 74 at a target site at the base of the bulge 76.
As shown in
As shown in
As shown in
The corners 34 of the support frame 20 slide along the segments 22B to which they are secured when the segments 22B rotate outwardly relative to one another. When comparing
After the device 10 is installed, the aneurysmic bulge 76, having been segregated from the remainder of the left ventricle 52A, eventually clots off behind the sheet 16, thereby effectively reducing the internal volume in the left ventricle 52A. Stretching of the portion of the myocardium 74 forming the aneurysmic bulge 76 is also effectively eliminated. By blocking off a portion of the left ventricle 52A not contributing to pumping during a systolic portion of a pump cycle, properly functioning portions of the myocardium 74 can contract normally and use up a normal amount of oxygen. By reducing the amount of oxygen uptake during a given period of time, properly functioning portions of the myocardium 74 are not exhausted and can continue to function properly. Cardiac output increases, and the likelihood of congestive heart failure is reduced, assuming that all other conditions remain the same. A reduction in the strength of the contractions of the properly functioning portions of the myocardium also reduces LVESP, with a corresponding reduction in stress of both dyskinetic and properly functioning portions of the myocardium 74.
In the given example, there are a total of 31 anchoring formations 14, including the distal anchoring screw 14A, 14 distal anchoring hooks 14B, and 16 proximal anchoring hooks 14C. The large number of anchoring formations 14 ensure proper anchoring to the myocardium 74. The large number of anchoring formations 14 also allows for positioning of the membrane 16 at a select location within the left ventricle 52A and at a select angle and within a select plane relative to the myocardium 74. The anchoring formations 14, and in particular the anchoring hooks 14B and 14C, their shape, orientation, and placement, are thus uniquely suited for anchoring of the frame construction 12, especially when compared with other anchoring formations such as pins, clamps, staples, screws, and surgical thread. What should also be noted is that the anchoring formations 14 penetrate through only a portion of the myocardium 74, and thus do not damage the pericardium. What should further be noted is that none of the anchoring formations 14 or other components of the device 10 can bump against the myocardium 74, to avoid electrostimulation of the myocardium 74 that can lead to arrhythmias.
Referring again to
The first row in the table lists the dimensions for the device 10 hereinbefore described which is used for blocking a relatively small aneurysmic bulge 76. Larger aneurysmic bulges can be blocked using slightly larger devices. As mentioned, certain diseases or alcoholism may cause general enlargement of endocardial cavities of a heart without necessarily creating a specific identifiable bulge. Larger devices can be used to block portions of these enlarged endocardial cavities. In such cases, it may also be possible to use two devices in a side-by-side arrangement or with their membranes overlapping one another.
The support frame of a device may be shaped so that a membrane attached to the support frame has a desired shape.
It may also be possible to use the same device to block off either large or small cavities.
The support frame and anchoring formations of, for example, the device illustrated in
In the embodiment illustrated in
Then the device 500 is deployed in an organ, the membrane 501 divides the organ into two separate compartments. Those compartments will be determined by the physician and typically will consist of a functional compartment and a nonfunctional compartment. For example, in the case of a left ventricular aneurysm (an enlargement of one small part of the left ventricular myocardium), the device is positioned at the mouth of the aneurysm 507, as illustrated in
In the case of congestive heart failure, the ventricle can similarly be divided into functional and nonfunctional parts, with improved overall ventricular performance. The elimination of one portion of the enlarged heart will prevent further cardiac enlargement and provide improved performance.
In the case of the stomach, the stomach could be divided into a nonfunctional part, i.e. the part which does not participate in digestion, and the remainder of the stomach which includes normal digestive processes.
The membrane is closely attached to the walls of the organ in order to prevent any communication between the two compartments. It can be elastic, non-elastic, non-porous, non-thrombogenic, and/or biocompatible. In one presently preferred embodiment, the membrane is fabricated of a mesh of elastin fibers (i.e. elastin proteins or a synthetic material) chosen to provide tensile strength and flexibility. The membrane can also have living cells (e.g., endothelial cells, myocytes, smooth muscle cells, or stem cells) and/or certain bioactive substances, such as heparin, on its surface.
In other embodiments, the membrane 501 can be rigid, or capable of changing size and shape to accommodate the size and shape of the organ. It can also be composed of hydrogels that change into a tendon-like structure and/or a bioresorbable material. It can also include a protein which will serve to attract the patient's own cells that will turn into myocytes and become a new myocardium.
As illustrated in
In operation, the instrument is inserted into the body of the patient, and operating rod 513 is moved forward to advance the partitioning device from the distal end of tubular body 512. As the device is moving forward, control knob is turned in a clockwise direction to extend the membrane, as illustrated in
In the embodiment illustrated in
he partitioning device can be implanted in a number of ways. It can, for example, be implanted by a surgeon during a surgical procedure. It can also be implanted through an endoscope or a laparoscope during a laparoscopic procedure. Similarly, it can be implanted through a thoracoscope during a thoracoscopic procedure, and it can be delivered to the inside of an organ through a long tubular device such as a catheter, either percutaneously, orally, or by some other minimally invasive approach.
If desired, more than one partitioning device can be employed, e.g. to treat more than one condition in an organ.
If desired, the partitioning devices can be constructed to facilitate removal from the hollow organ after a period of time. In the case of morbid obesity, for example, the devices can be implanted in the stomach, and in the event that they becomes too uncomfortable, they can be removed in the same manner in which they were installed.
The invention has a number of important features and advantages. It permits diseases caused by dysfunction of hollow organs to be treated simply and effectively without difficult surgical procedures.
While particular forms of the invention have been illustrated and described herein, it will be apparent that various modifications and improvements can be made to the invention. For example an inflatable dividing element may be used to occlude an atrial appendage of the heart. Moreover, individual features of embodiments of the invention may be shown in some drawings and not in others, but those skilled in the art will recognize that individual features of one embodiment of the invention can be combined with any or all the features of another embodiment. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated. It is intended that this invention to be defined by the scope of the appended claims as broadly as the prior art will permit.
Terms such a “element”, “member”, “device”, “section”, “portion”, “steps”, “means” and words of similar import when used herein shall not be construed as invoking the provisions of 35 U.S.C. §112(16) unless the following claims expressly use the terms “means” followed by a particular function without specific structure or “step”followed by a particular function without specific action. All patents and patent applications referred to above are hereby incorporated by reference in their entirety. Accordingly, it is not intended that the invention be limited, except as by the appended claims.
The present patent application is a continuation-in-part application of prior U.S. patent application No. 09/635,511, filed on Aug. 9, 2000, now abandoned, which claims priority from U.S. Provisional Patent Application No. 60/147,894 filed on Aug. 9,1999, and are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3874388 | King et al. | Apr 1975 | A |
4007743 | Blake | Feb 1977 | A |
4425908 | Simon | Jan 1984 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4832055 | Palestrant | May 1989 | A |
4917089 | Sideris | Apr 1990 | A |
5104399 | Lazarus | Apr 1992 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5375612 | Cottenceau et al. | Dec 1994 | A |
5385156 | Oliva | Jan 1995 | A |
5425744 | Fagan et al. | Jun 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5451235 | Lock et al. | Sep 1995 | A |
5496277 | Termin et al. | Mar 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5549621 | Bessler et al. | Aug 1996 | A |
5578069 | Miner, II | Nov 1996 | A |
5634936 | Linden et al. | Jun 1997 | A |
5634942 | Chevillon et al. | Jun 1997 | A |
5702343 | Alferness | Dec 1997 | A |
5709707 | Lock et al. | Jan 1998 | A |
5791231 | Cohn et al. | Aug 1998 | A |
5797849 | Vesely et al. | Aug 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5833698 | Hinchliffe et al. | Nov 1998 | A |
5836968 | Simon et al. | Nov 1998 | A |
5843170 | Ahn | Dec 1998 | A |
5861003 | Latson et al. | Jan 1999 | A |
5865730 | Fox et al. | Feb 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5871017 | Mayer | Feb 1999 | A |
5875782 | Ferrari et al. | Mar 1999 | A |
5876325 | Mizuno et al. | Mar 1999 | A |
5876449 | Starck et al. | Mar 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5882340 | Yoon | Mar 1999 | A |
5910150 | Saadat | Jun 1999 | A |
5916145 | Chu et al. | Jun 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5925076 | Inoue | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5961440 | Schweich, Jr. et al. | Oct 1999 | A |
5961539 | Northrup, III et al. | Oct 1999 | A |
5984917 | Fleischman et al. | Nov 1999 | A |
6024096 | Buckberg | Feb 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6045497 | Schweich et al. | Apr 2000 | A |
6059715 | Schweich et al. | May 2000 | A |
6076013 | Brennan et al. | Jun 2000 | A |
6077214 | Mortier et al. | Jun 2000 | A |
6077218 | Alferness | Jun 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6095968 | Snyders | Aug 2000 | A |
6096347 | Geddes et al. | Aug 2000 | A |
6099832 | Mickle et al. | Aug 2000 | A |
6102887 | Altman | Aug 2000 | A |
6125852 | Stevens et al. | Oct 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6193731 | Oppelt et al. | Feb 2001 | B1 |
6221092 | Koike et al. | Apr 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6258021 | Wilk | Jul 2001 | B1 |
6267772 | Mulhauser et al. | Jul 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6312446 | Huebsch et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6343605 | Lafontaine | Feb 2002 | B1 |
6348068 | Campbell et al. | Feb 2002 | B1 |
6355052 | Neuss et al. | Mar 2002 | B1 |
6360749 | Jayaraman | Mar 2002 | B1 |
6364896 | Addis | Apr 2002 | B1 |
6387042 | Herrero | May 2002 | B1 |
6406420 | McCarthy et al. | Jun 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6450171 | Buckberg et al. | Sep 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6537198 | Vidlund et al. | Mar 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6592608 | Fisher et al. | Jul 2003 | B2 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6685627 | Jayaraman | Feb 2004 | B2 |
6852076 | Nikolic et al. | Feb 2005 | B2 |
20010014800 | Frazier et al. | Aug 2001 | A1 |
20020019580 | Lau et al. | Feb 2002 | A1 |
20020026092 | Buckberg et al. | Feb 2002 | A1 |
20020028981 | Lau et al. | Mar 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020055767 | Forde et al. | May 2002 | A1 |
20020055775 | Carpentier et al. | May 2002 | A1 |
20020161394 | Macoviak et al. | Oct 2002 | A1 |
20020169359 | McCarthy et al. | Nov 2002 | A1 |
20020169360 | Taylor et al. | Nov 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20030109770 | Sharkey et al. | Jun 2003 | A1 |
20030149333 | Alferness | Aug 2003 | A1 |
20050154252 | Sharkey et al. | Jul 2005 | A1 |
20050197716 | Sharkey et al. | Sep 2005 | A1 |
20050216052 | Mazzocchi et al. | Sep 2005 | A1 |
20060014998 | Sharkey et al. | Jan 2006 | A1 |
20060030881 | Sharkey et al. | Feb 2006 | A1 |
Number | Date | Country |
---|---|---|
WO 0027292 | May 2000 | WO |
WO 0130266 | May 2001 | WO |
WO 0178625 | Oct 2001 | WO |
WO 0230335 | Apr 2002 | WO |
WO 02071977 | Sep 2002 | WO |
WO 03007778 | Jan 2003 | WO |
WO 2004012629 | Feb 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20030050685 A1 | Mar 2003 | US |
Number | Date | Country | |
---|---|---|---|
60147894 | Aug 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09635511 | Aug 2000 | US |
Child | 10212032 | US |